Isolation of prostate cancer-related exosomes

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3419-3423

  Mizutani, Kosuke ^a   Terazawa, Riyako ^a   Kameyama, Koji ^a   Kato, Taku ^a   Horie, Kengo ^a   Tsuchiya, Tomohiro ^a   Seike, Kensaku ^a   Ehara, Hidetoshi ^b   Fujita, Yasunori ^c   Kawakami, Kyojiro ^c   Ito, Masafumi ^c   Deguchi, Takashi ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ASAHI UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

Androgen receptor; Exosome; LNCaP; Microvesicle; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

ANDROGEN RECEPTOR; ANTIBODY; BICALUTAMIDE; CD9 ANTIBODY; DOCETAXEL; PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ARTICLE; BLOOD; CANCER CELL LINE; CANCER PATIENT; CELL ISOLATION; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; METASTASIS; PC3 CELL LINE; PLASMA; PROSTATE CANCER; ULTRACENTRIFUGATION; WESTERN BLOTTING; CANCER STAGING; CASE CONTROL STUDY; CASTRATION RESISTANT PROSTATE CANCER; CHEMISTRY; MICROVESICLE; PATHOLOGY; PROSTATE-SPECIFIC MEMBRANE ANTIGEN; TUMOR CELL LINE; ULTRASTRUCTURE;

ANDROGEN RECEPTOR; EXOSOME; LNCAP; MICROVESICLE; PROSTATE CANCER; PROSTATE-SPECIFIC MEMBRANE ANTIGEN;

BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; EXOSOMES; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; ULTRACENTRIFUGATION;

EID: 84906324490     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Formand: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M and Tannock IF: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242-245, 2008.
3. Koul HK, Pal M and Koul S: Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 4: 342-359, 2013.
4. Bitting RL and Armstrong AJ: Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 20: R83-99, 2013.
5. Karantanos T, Corn PG and Thompson TC: Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32: 5501-11, 2013.
6. Azmi AS, Bao B and Sarkar FH: Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev 32: 623-42, 2013.
7. Soekmadji C, Russell PJ and Nelson CC: Exosomes in prostate cancer: putting together the pieces of a puzzle. Cancers 5: 1522-44, 2013.
8. Chen C, Skog J, Hsu CH, Lessard RT, Balaj L, Wurdinger T, Carter BS, Breakefield XO, Toner M and Irimia D: Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip 10: 505-511, 2010.
9. Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, Nolte-'t Hoen EN, Piper MG, Sivaraman S, Skog J, Théry C, Wauben MH and Hochberg F: Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles 2: 20360, 2013.
10. Friedlander TW and Ryan CJ: Targeting the androgen receptor. Urol Clin North Am 39: 453-464, 2012.
11. Coffey K and Robson CN: Regulation of the androgen receptor by post-translational modifications. J Endocrinol 215: 221-237, 2012.
12. Sweat SD, Pacelli A, Murphy GP and Bostwick DG: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52: 637-640, 1998.
13. Elgamal AA, Holmes EH, Su SL, Tino WT, Simmons SJ, Peterson M, Greene TG, Boynton AL and Murphy GP: Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol 18: 10-16, 2000.
14. Ristau BT, O'Keefe DS and Bacich DJ: The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research. Urol Oncol 32: 272-279, 2014.
15. Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z and Clayton A: Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med 7: 4, 2009.
16. Miyamoto H, Messing EM and Chang C: Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61: 332-353, 2004.
17. Shore N, Mason M and de Reijke TM: New developments in castrate-resistant prostate cancer. BJU Int 109(Suppl 6): 22-32, 2012.